Effects of daily vitamin D supplementation on respiratory muscle strength and physical performance in vitamin D-deficient COPD patients: a pilot trial

Abstract

Background

Although vitamin D is well known for its function in calcium homeostasis and bone mineralization, several studies have shown positive effects on muscle strength and physical function. In addition, vitamin D has been associated with pulmonary function and the incidence of airway infections. As vitamin D deficiency is highly prevalent in chronic obstructive pulmonary disease (COPD) patients, supplementation might have a beneficial effect in these patients.

Objective

To assess the effect of vitamin D supplementation on respiratory muscle strength and physical performance in vitamin D-deficient COPD patients. Secondary outcomes are pulmonary function, handgrip strength, exacerbation rate, and quality of life.

Methods

We performed a randomized, double-blind, placebo-controlled pilot trial. Participants were randomly allocated to receive 1,200 IU vitamin D3 per day (n=24) or placebo (n=26) during 6 months. Study visits were conducted at baseline, and at 3 and 6 months after randomization. During the visits, blood was collected, respiratory muscle strength was measured (maximum inspiratory and expiratory pressure), physical performance and 6-minute walking tests were performed, and handgrip strength and pulmonary function were assessed. In addition, participants kept a diary card in which they registered respiratory symptoms.

Results

At baseline, the mean (standard deviation [SD]) serum 25-hydroxyvitamin D (25(OH)D) concentration (nmol/L) was 42.3 (15.2) in the vitamin D group and 40.6 (17.0) in the placebo group. Participants with vitamin D supplementation had a larger increase in serum 25(OH)D compared to the placebo group after 6 months (mean difference (SD): +52.8 (29.8) vs +12.3 (25.1), P<0.001). Primary outcomes, respiratory muscle strength and physical performance, did not differ between the groups after 6 months. In addition, no differences were found in the 6-minute walking test results, handgrip strength, pulmonary function, exacerbation rate, or quality of life.

Conclusion

Vitamin D supplementation did not affect (respiratory) muscle strength or physical performance in this pilot trial in vitamin D-deficient COPD patients.

Keywords:

• chronic obstructive pulmonary disease
• vitamin D
• physical performance
• muscle strength
• pulmonary function

Background

Vitamin D deficiency in patients with chronic obstructive pulmonary disease (COPD) is highly prevalent and associated with disease severity.^1,2 Although vitamin D is classically known for its function in calcium and bone metabolism, studies in the past decades have suggested a far broader range of physiological effects of vitamin D, including effects on muscle function and the immune system, linked to the presence of vitamin D receptors (VDR) on the cells of these tissues.³ These effects might have clinical implications for patients with COPD.⁴

Impaired muscle function and poor physical performance form a major part of the disease burden in patients with COPD.⁵ Quadriceps and handgrip weakness as well as poorer score in the 6-minute walking test are predictors of increased mortality risk in COPD patients.^6–8 In the general population, several meta-analyses of randomized clinical trials have shown positive effects of vitamin D supplementation on muscle strength and physical performance.^9–11 This effect was larger in participants with severe vitamin D deficiency at baseline.^11,12 Observational studies on the relationships between vitamin D status and muscle function in COPD patients are controversial, although a polymorphism in the VDR gene has been shown to affect quadriceps muscle strength.^5,13,14 Only two intervention studies have been carried out in COPD patients without vitamin D deficiency selection. These studies were too small to perform post hoc analyses in deficient groups. Therefore, there is a need to specifically study COPD patients with vitamin D deficiency.

Besides muscle strength and physical function, some observational studies have shown that serum 25-hydroxyvitamin D (25(OH)D) concentrations are positively associated with pulmonary function.^15,16 One hypothesis for this relationship is that vitamin D might affect pulmonary function through beneficial effects on muscle strength:⁵ worse muscle function might lead to impaired respiratory muscle strength and thus poor pulmonary function.

These findings have led us to the question of whether vitamin D supplementation might influence disease course through an effect on muscle function in COPD patients. Vitamin D might be an attractive treatment option, as it is easy, safe, and inexpensive. With this study, we aim to assess the effects of vitamin D supplementation on respiratory muscle strength and physical performance specifically in vitamin D-deficient COPD patients. In addition, we assess its effects on pulmonary function, hand grip strength, exacerbation rate, and quality of life.

Methods

Study design and participants

We performed a randomized placebo-controlled trial in two centers. Participants were recruited from the departments of pulmonary disease of a university medical center (VU University Medical Center) and a large teaching hospital (Northwest Hospital group) in the period 2012–2014. Patients with COPD who met the inclusion criteria were asked to participate in the study (Table 1). If patients agreed to participate, their serum 25(OH)D concentration was assessed. Patients who had a vitamin D deficiency (25(OH)D <50 nmol/L) were included in the study. Study visits took place at baseline and after 3 and 6 months. All participants provided written informed consent. The study was approved by the local medical ethics committee of the VU University Medical Center and Northwest Hospital group (NL36386.029). The study was registered in the Netherlands Trial Register (NTR2827).

Table 1 Eligibility criteria

Inclusion criteria	Exclusion criteria
Vitamin D deficiency (serum 25(OH)D <50 nmol/L)	Severe vitamin D deficiency (25(OH)D <15 nmol/L)
Post-bronchodilator FEV1/FVC <0.70, FEV1 <80% of predicted and COPD diagnosis confirmed by a physician	Clinical suspicion of osteoporosis
Age 40–70 years	Interfering malignant disease
Written informed consent	Life expectation of <6 months on the basis of concurrent disease
Ability to comply with all study requirements	Pregnant or lactating women, or subjects who intend to become pregnant within the study period
	Potentially unreliable patients and those judged by the investigator to be unsuitable for the study
	Serious mental impairment, ie, preventing understanding of the study protocol or compliance with the study aim

Abbreviations: 25(OH)D, 25-hydroxyvitamin D; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity.

Randomization and masking

Participants were allocated by computer-generated block randomization (blocks of four patients) to receive either vitamin D or placebo with stratification by gender and institution. Pharmacists of the VU University Medical Center, who were independent from the clinical study team, performed the allocation. After the last participant completed the study, masking continued until all analyses were performed.

Intervention

Participants received either 1,200 IU colecalciferol or a matching placebo during 6 months according to randomization. They were allowed to use vitamin D supplementation to a maximum of 400 IU/day, as advised by the Dutch Health Council for adults aged <70 years. During the study, the participants were advised to ensure a dietary calcium intake of at least 1,000 mg per day. If this was not feasible, they received calcium supplementation to ensure a total calcium intake of 1,000 mg/day, as advised by the Dutch Health Council.

Outcomes

Primary outcomes

Primary outcomes were respiratory muscle strength and physical performance. Respiratory muscle strength was assessed by measuring maximal inspiratory and expiratory pressure according to American Thoracic Society (ATS) and European Respiratory Society (ERS) guidelines.¹⁷ Physical performance score was assessed by the tandem test, chair stands test, 3-m walking test, and 6-minute walking test.^18,19 The tandem test is a measure which estimates balance. The chair stands test largely represents quadriceps muscle strength as well as balance and the 3-meter walking test depicts a combination of gait performance and balance. The 6-minute walking test measures general functional exercise capacity.

Secondary outcomes

Secondary outcomes in this study were forced expiratory volume in 1 second and forced vital capacity measured by spirometry according to ATS/ERS guidelines,²⁰ peak expiratory flow determined using the Mini-Wright peak flow meter, handgrip muscle strength measured using a dynamometer,²¹ and scores on physical activity measured by LASA Physical Activity Questionnaire (LAPAQ).²² LAPAQ is a questionnaire covering several areas of activities. Scores are presented as activity in minutes per day and can be separated into sports and non-sports activities. In addition, participants were asked to maintain a diary card during the whole study period, in which they registered the occurrence of exacerbations and changes in medication. An exacerbation was defined as the presence, for at least 2 consecutive days, of an increase in any two major symptoms (dyspnea, sputum purulence, sputum amount) or an increase in one major and one minor symptom (wheeze, sore throat, cough, symptoms of a common cold).²³ Finally, quality of life was assessed using the Short Form Health Survey (SF-12)²⁴ and EuroQol (EQ-5D) questionnaires.²⁵ SF-12 can be subdivided into a physical and mental component summary and is scored within the 0–100 range, with a higher score indicating better quality of life. The EQ-5D score ranges from 0 to 1 with 1 indicating perfect health status.

25(OH)D

Blood samples were drawn from all participants at baseline and after 6 months. Samples were centrifuged and stored at −80°C until determination. After the study was completed, 25(OH)D was assessed in all samples by isotope dilution-solid phase extraction liquid chromatography-tandem mass spectrometry at the Endocrine Laboratory of the VU University Medical Center as described before.²⁶ The limit of quantitation was 4.0 nmol/L, intra-assay coefficient of variation (CV) was <6%, and inter-assay CV was <8% for concentrations between 25 and 180 nmol/L. 25(OH)D₂ and 25(OH)D₃ were measured separately.

Statistical analyses

At the start of this study, no trials on the effects of vitamin D supplementation in patients with COPD had been performed. Therefore, there were no data available on which we could base a sample size calculation. Because of the pilot nature of the study, we decided to include 50 participants.

All analyses were performed using the intention-to-treat analysis. In addition, sensitivity analyses including only severe vitamin D-deficient participants (<25 nmol/L) were performed to assess potential effects in this group. Finally, we also performed a subgroup analysis excluding noncom-pliant participants and participants who had used vitamin D supplementation.

Data are presented as mean ± standard deviation (sd), median (interquartile range) if data were not normally distributed or as number (%). We tested for differences between the placebo and vitamin D group at baseline and for differences between the groups in changes after 6 months. We used an unpaired t-test to test for normally distributed continuous variables, Mann–Whitney test for skewed continuous variables, and Pearson χ² tests for categorical variables. All analyses were performed using IBM SPSS Statistics for Windows, version 22 (IBM Corporation, Armonk, NY, USA).

Results

We screened 233 patients with COPD for vitamin D deficiency (Figure 1). Of these patients, 145 did not meet the inclusion criteria and 38 did not want to participate in the study. Eventually, 50 participants were randomized to receive either placebo (n=26) or vitamin D supplementation (n=24). After randomization, one participant was excluded from the study, because he was wheelchair-bound and could not comply with all the study requirements. During follow-up, six participants withdrew consent.

Figure 1 Flowchart study.

Abbreviations: 25(OH)D, 25-hydroxyvitamin D; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity.

Table 2 shows the baseline characteristics for both subgroups. Mean serum 25(OH)D levels were deficient in both groups (mean serum 25(OH)D in nmol/L (SD): 42.3 (15.2) and 40.6 (17.0) in the vitamin D and placebo groups, respectively). The placebo group scored slightly better in the 3-meter walking test. No other differences between the groups were detected.

Table 2 Baseline characteristics

	Placebo (n=26)	Vitamin D (n=24)	P-value
Age (years)	61 [58–66]	64 [61–66]	0.448
Gender
Male	13 (50)	13 (54.2)	0.768
Female	13 (50)	11 (45.8)
Smoking
Former	8 (30.8)	6 (25.0)	0.650
Current	18 (69.2)	18 (75.0)
Pack-years	30.9±18.5	33.5±20.2	0.627
BMI (kg/m^2)	26.4±5.1	29.6±6.7	0.063
Serum 25(OH)D (nmol/L)	40.6±17.0	42.3±15.2	0.709
Serum 25(OH)D <25 nmol/L	2 (7.7)	4 (16.7)	0.329
Vitamin D supplementation	7 (27)	6 (25)	0.877
GOLD stage
I	4 (15.4)	6 (25.0)	0.415
II	14 (53.8)	8 (33.3)
III	5 (19.2)	8 (33.3)
IV	3 (11.5)	2 (8.3)
Pulmonary function
PEF (L)	5.47±2.22	4.75±2.46	0.284
PEF (% predicted)	73.95±24.71	66.71±27.66	0.333
FEV1 (L)	1.67 [1.10–2.16]	1.51 [1.21–1.74]	0.528
FEV1 (% predicted)	58.95±23.03	58.46±21.23	0.938
FVC (L)	3.52±1.16	3.37±0.89	0.604
FVC (% predicted)	97.08±22.23	98.28±18.72	0.838
FEV1/FVC	48.46±12.51	48.76±15.01	0.939
Hand peak flow (L/s)	240 [190–375]	235 [168–291]	0.417
Respiratory muscle strength (kPa)
MIP	8.27±2.58	7.32±2.36	0.195
MEP	12.12±4.36	11.10±3.65	0.390
Maximal hand grip strength (kg)	34.68±9.86	34.13 (9.92)	0.845
SPPB (time in s)
3-m walking test	4.5 [4.0–5.0]	5.0 [5.0–6.3]	0.019
Chair stands test	10.0 [8.8–12.3]	11.0 [9.0–13.0]	0.601
Tandem test	7.0 [3.0–10.0]	6.0 [4.0–9.0]	0.803
6-minute walking test (m)	416.70±87.15	393.15±92.82	0.375
LAPAQ (min/day)
Total activity	174±118	133±83	0.168
Sports activity	13 [0–26]	0 [0–17]	0.530
EQ-5D	0.81 [0.76–0.92]	0.78 [0.78–0.84]	0.402
SF-12
PCS	35.07±9.19	38.24±10.55	0.283
MCS	53.08±9.10	53.61±7.09	0.831

Note: Data are presented as mean ± SD, number (%) or median [interquartile range].

Abbreviations: 25(OH)D, 25-hydroxyvitamin D; BMI, body mass index; GOLD, Global Initiative for Chronic Obstructive Lung Disease; PEF, peak expiratory flow; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; SPPB, short physical performance battery; LAPAQ, LASA Physical Activity Questionnaire; EQ-5D, EuroQol questionnaire; SF-12, Short Form Health Survey; PCS, physical component summary; MCS, mental component summary; MIP, maximum inspiratory pressure; MEP, maximum expiratory pressure.

In Table 3, the differences after 6 months are shown for both groups. The vitamin D group showed a significant increase in serum 25(OH)D levels compared to the placebo group (mean difference (SD): +52.8 (29.8) vs +12.3 (25.1), P<0.001). We did not find any differences between the changes in pulmonary muscle strength and physical performance scores after 6 months. In addition, no differences were found in changes of the secondary outcomes (pulmonary function, handgrip strength, exacerbation rate, or quality of life). Sensitivity analyses in severe vitamin D-deficient participants (n=6) and subgroup analyses excluding noncom-pliant participants (n=9) also did not show any differences (data not shown). A subgroup analysis excluding participants with self-administered vitamin D supplementation also did not show any differences (Table S1).

Table 3 Differences (Δ) after 6 months

	Placebo (n=24)	Vitamin D (n=19)	P-value
Serum 25(OH)D (nmol/L)	+12.3±25.1	+52.8±29.8	<0.001
BMI (kg/m^2)	−0.06±0.96	+0.01±0.93	0.799
Pulmonary function
PEF (L)	−0.17 [−0.40 to 0.58]	+0.16 [−0.35 to 0.85]	0.533
PEF (% predicted)	+0.96±10.50	+4.78±15.74	0.346
FEV1 (L)	+0.05 [−0.06 to 0.27]	−0.01 [−0.07 to 0.10]	0.255
FEV1 (% predicted)	+3.46±8.05	+0.21±4.25	0.120
FVC (L)	+0.11±0.27	+0.05±0.17	0.393
FVC (% predicted)	+3.86±8.31	+0.81±5.52	0.176
FEV1/FVC	+0.99±4.38	−0.34±3.02	0.267
Hand peak flow (L/s)	+5 [−15 to 45]	+0 [−25 to 35]	0.685
Respiratory muscle strength (kPa)
MIP	−0.19±1.45	+0.25±1.22	0.306
MEP	−0.35±3.48	+0.51±2.07	0.350
Maximal hand grip strength (kg)	+0.16±3.89	−0.04±2.73	0.847
SPPB (time in s)
3-m walking test	+0.0 [0.0–1.0]	+0.0 [−1.0 to 0.0]	0.054
Chair stands test	+0.0 [−2.0 to 1.0]	−1.0 [−3.0 to 0.0]	0.189
Tandem test	+0.76±2.39	−0.69±3.43	0.180
6-minute walking test (m)	+14.2 [−22.4 to 70.5]	−3.7 [−19.0 to 27.3]	0.597
LAPAQ (min/day)
Total activity	−22 (94)	−5 (68)	0.518
Sports activity	0 [−7 to 6]	0 [−5 to 2]	0.927
EQ-5D	+0.00 [0.00–0.11]	+0.00 [−0.14 to 0.04]	0.080
SF-12
PCS12	+4.06±6.37	+1.14±6.77	0.186
MCS12	+1.38±8.49	−1.15±8.41	0.373
Number of exacerbations	1 [0–2]	0 [0–2]	0.480

Note: Data are presented as mean ± SD or median [interquartile range].

Abbreviations: 25(OH)D, 25-hydroxyvitamin D; BMI, body mass index; PEF, peak expiratory flow; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; SPPB, short physical performance battery; LAPAQ, LASA Physical Activity Questionnaire; EQ-5D, EuroQol questionnaire; SF-12, Short Form Health Survey; PCS, physical component summary; MCS, mental component summary; MIP, maximum inspiratory pressure; MEP, maximum expiratory pressure; SD, standard deviation.

No differences were found between the vitamin D group and placebo group after 3 months (Table S2).

Discussion

This pilot study aimed to assess the effects of vitamin D supplementation on respiratory muscle strength and physical performance in patients with COPD. To the best of our knowledge, this is the first study that has been performed in COPD patients with a vitamin D deficiency. We did not find any effect of vitamin D supplementation on respiratory muscle strength or physical performance. In addition, we did not find any effects on the secondary outcomes – pulmonary function, hand grip strength, exacerbation rate, and quality of life.

While several observational studies point toward a positive relationship between vitamin D and physical performance in the general population, the number of randomized clinical trials to study a potential causal effect remains very limited. Two trials have assessed the effect of vitamin D supplementation on physical performance in patients with COPD. The first study was a post hoc subgroup analysis of a larger trial assessing the effects of vitamin D supplementation to reduce exacerbations. In this subgroup study, the effects of vitamin D were studied during a rehabilitation program.²⁷ Participants (n=50) received a monthly dose of 100,000 IU vitamin D during 3 months. Vitamin D supplementation did not influence physical performance as compared to placebo, although it was related to a slight increase in inspiratory muscle strength. In the second study, participants (n=36) received a daily dose of 2,000 IU vitamin D during 6 weeks. Vitamin D supplementation also did not affect physical performance score in this study.²⁸ These findings are in line with our results. Both previous studies did not select patients with vitamin D deficiency at baseline.

Trials assessing the effects of vitamin D supplementation in the general population show conflicting results. One meta-analysis showed no effects of vitamin D supplementation on muscle strength in the general adult population, except in participants with 25(OH)D concentrations <25 nmol/L at baseline.¹² Another meta-analysis, including only studies in participants aged ≥60 years, did show an effect on muscle strength and balance.⁹ This might suggest that a potential effect is only relevant in older and vitamin D-deficient participants. This was indeed confirmed in a meta-analysis by Beaudart et al¹¹ which showed a larger effect of vitamin D supplementation on global muscle strength in participants with baseline 25(OH)D levels <30 nmol/L and participants aged >65 years. A more recent meta-analysis in participants aged ≥65 years, however, did not show an effect of vitamin D supplementation on muscle strength.²⁹ A subgroup analysis of participants with serum 25(OH)D <25 nmol/L in our study did not show any effect. This group, however, was very small (n=6), because we excluded patients with severe vitamin D deficiency (<15 nmol/L), due to ethical considerations. We also excluded participants aged >70 years, because the Dutch Health Council recommends vitamin D supplementation in this population. This has led to a lower mean age of our study population compared to other trials.

Two other trials assessing the effects of vitamin D supplementation in COPD have been reported since the start of our study.^30,31 The primary outcome of both studies was exacerbation rate. Both studies did not show an effect of vitamin D supplementation in the total study population, but did find an effect in their subgroup analysis of participants with a (severe) vitamin D deficiency. In our study, we assessed exacerbation rate as a secondary outcome. However, we did not find any differences between the supplementation group and the placebo group. This might be explained by the differences in inclusion criteria. In both the previous studies, participants were included if they had had ≥1 exacerbations in the past year. In our study, however, having an exacerbation in the preceding year was not an inclusion criterion. This might have led to the selection of COPD patients with a milder disease course. As stated earlier, we excluded patients with severe vitamin D deficiency (<15 nmol/L) in our study, which might have affected our outcomes, as a potential effect of vitamin D supplementation is expected to be stronger in patients with lower vitamin D levels.

A major limitation of our study is the small sample size. As this was considered a pilot trial, we only included 50 participants. This number was chosen as no previous trials were performed on which sample size could be calculated. However, we did not observe any differences which might have reached statistical significance in a larger study population.

Another limitation is the relatively low dose used in our study compared to previous studies. Because the threshold of vitamin D levels for extra-skeletal effects is currently not known, our dose might have been too low to provide a clinical effect. In addition, we used a daily dosing regimen, which leads to more stable levels, but can decrease participants’ compliance. However, participants in the supplementation group showed a significant increase in serum 25(OH)D levels, reaching a mean level of 96 nmol/L after 6 months, which is considered sufficient and comparable to levels reached in other studies. A subgroup analysis excluding noncompliant participants did also not affect our results.

To conclude, this trial did not show an effect of vitamin D supplementation on respiratory muscle strength and physical performance. It has shown several factors that can be addressed in future studies. The daily dosing regimen of 1,200 IU might be too low for a clinical effect in patients with COPD. In addition, our study population might have been too good to show a potential effect. Since the start of our study, two other trials assessing the effects of vitamin D supplementation in COPD have been reported.^30,31 These trials did show an effect of vitamin D supplementation on exacerbation rate in subgroups of deficient participants. Therefore, we are currently performing an additional large multicenter trial on the effects of vitamin D supplementation in COPD patients with a vitamin D deficiency (ClinicalTrials.gov, ID number NCT2122627).³² Primary outcome in this study is exacerbation rate, but muscle strength and physical performance are secondary outcomes. In this trial, we selected patients that have had an exacerbation in the previous year. In addition, we have increased the supplementation dose to 16,800 IU a week and extended the follow-up to 1 year. This trial is still ongoing and expected to be completed in 2018.

Author contributions

All authors have made substantial contributions to the conception and design of this study. All were equally involved in drafting the manuscript or revising it critically and have given final approval of the version to be published.

Supplementary materials

Table S1 Differences (Δ) after 6 months with exclusion of participants using vitamin D supplements

	Placebo (n=20)	Vitamin D (n=15)	P-value
Serum 25(OH)D (nmol/L)	+9.1±25.0	+55.8±32.2	<0.001
BMI (kg/m^2)	+0.03±0.82	−0.11±0.95	0.645
Pulmonary function
PEF (L)	−0.03 [−0.35 to 0.68]	+0.08 [−0.45 to 0.68]	0.764
PEF (% predicted)	+2.60±0.30	+3.39±16.31	0.861
FEV1 (L)	+0.05 [−0.08 to 0.30]	−0.01 [−0.07 to 0.10]	0.433
FEV1 (% predicted)	+3.55±8.78	+0.13±4.41	0.143
FVC (L)	+0.11±0.29	+0.04±0.19	0.412
FVC (% predicted)	+3.70±8.92	+0.29±6.02	0.210
FEV1/FVC	+1.16±4.76	−0.14±3.22	0.369
Hand peak flow (L/s)	+5 [−15 to 49]	−5 [−30 to 0]	0.432
Respiratory muscle strength (kPa)
MIP	+0.01±1.35	+0.13±1.25	0.805
MEP	−0.70±3.00	+0.27±1.89	0.286
Maximal hand grip strength (kg)	+0.34±4.16	−0.37±2.92	0.581
SPPB (time in s)
3-meter walking test	+0.0 [0.0–1.0]	+0.0 [−1.0 to 0.0]	0.049
Chair stands test	−1.0 [−2.0 to 1.0]	−1.0 [−2.0 to 0.0]	0.574
Tandem test	+0.46±2.15	−0.45±3.45	0.435
6-minute walking test (m)	+6.0 [−22.4 to 58.0]	−6.0 [−20.3 to 27.3]	0.610
LAPAQ (min/day)
Total activity	−15±97	−2±64	0.655
Sports activity	0 [−16 to 6]	0 [−5 to 2]	0.913
EQ-5D	+0.00 [0.03–0.12]	+0.00 [−0.13 to 0.07]	0.156
SF-12
PCS12	+4.16±7.03	+0.98±7.13	0.232
MCS12	+1.38±7.45	−2.15±8.33	0.230
Number of exacerbations	1 [0–2]	0 [0–2]	0.507

Note: Data are presented as mean ± SD or median [interquartile range].

Abbreviations: 25(OH)D, 25-hydroxyvitamin D; BMI, body mass index; PEF, peak expiratory flow; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; SPPB, short physical performance battery; LAPAQ, LASA Physical Activity Questionnaire; EQ-5D, EuroQol questionnaire; SF-12, Short Form Health Survey; PCS, physical component summary; MCS, mental component summary; MIP, maximum inspiratory pressure; MEP, maximum expiratory pressure; SD, standard deviation.

Table S2 Differences (Δ) after 3 months

	Placebo (n=23)	Vitamin D (n=21)	P-value
BMI (kg/m^2)	+0.20±0.54	−0.01±0.65	0.250
Hand peak flow (L/s)	+10 [−30 to 40]	+10 [−33 to 43]	0.888
Maximal hand grip strength (kg)	−0.81±4.18	−0.07±2.58	0.484
SPPB (time in s)
3-meter walking test	+0.0 [−0.5 to 0.0]	+0.0 [−0.8 to 0.0]	0.739
Chair stands test	+0.0 [−1.0 to 1.0]	+0.0 [−2.0 to 0.8]	0.202
Tandem test	+0.50±3.79	−0.15±4.08	0.650
6-minute walking test (m)	+1.9 [−20.0 to 40.0]	−2.5 [−27.5 to 11.4]	0.358
LAPAQ (min/day)
Total activity	−6±82	+12±99	0.494
Sports activity	0 [−11 to 0]	0 [0–0]	0.127
EQ-5D	+0.00 [−0.09 to 0.09]	+0.00 [0.00–0.06]	0.991
SF-12
PCS12	+3.56±8.40	−1.54±5.32	0.239
MCS12	−1.58±8.87	−0.77±9.58	0.781
Number of exacerbations	0 [0–1]	0 [0–1]	0.573

Note: Data are presented as mean ± SD or median [interquartile range].

Abbreviations: BMI, body mass index; SPPB, short physical performance battery; LAPAQ, LASA Physical Activity Questionnaire; EQ-5D, EuroQol questionnaire; SF-12, Short Form Health Survey; PCS, physical component summary; MCS, mental component summary; SD, standard deviation.

Disclosure

The authors report no conflicts of interest in this work.